Custom panels
Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy | Ghidini M, et al. | Clin Cancer Res. | Dec. 2024
Michele Ghidini, Jens Claus Hahne, Chiara Senti, Timon Heide, Paula Z Proszek, Ridwan Shaikh, Paul Carter, Mike Hubank, et al. Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy. Clinical Cancer Research; 2025: 31, (4) 707-718. Nonacus product: Custom panels Background Eight hundred sixty-two plasma samples were collected 4-weekly…
Read More726P Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma | Ronchi CL, et al. | Annals of Oncology | Oct. 2023
Ronchi CL, Lippert J, Smith G, Altieri B, Elhassan YS, Landwehr LS, et al. 726P Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma. Annals of Oncology. 2023;34:S500. Nonacus product: Custom panels Background Adrenocortical carcinoma (ACC) is a rare aggressive endocrine cancer with heterogeneous behaviour. Disease surveillance relies on…
Read MoreOR04-5 Circulating cell-free DNA-based biomarkers For prognostication and disease surveillance in adrenocortical carcinoma | Altieri B, et al | Journal of the Endocrine Society | Nov. 2022
Lippert J, Smith G, Appenzeller S, Landwehr LS, Prete A, Steinhauer S, et al. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma. European Journal of Endocrinology. 2024;lvae022. Nonacus products: Sample collection and isolation / Custom panels Abstract Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on…
Read MoreCustom panel implementation in patients with non-syndromic autism spectrum disorders in the clinical routine of a tertiary hospital | Sandoval-Talamantes AK, et al | Genes | Nov. 2023
Sandoval-Talamantes AK, Tenorio-Castaño JA, Santos-Simarro F, Adán C, Fernández-Elvira M, García-Fernández L, et al. NGS Custom Panel Implementation in Patients with Non-Syndromic Autism Spectrum Disorders in the Clinical Routine of a Tertiary Hospital. Genes. 2023 ;14(11):2091. Nonacus product: Custom panels Abstract Autism spectrum disorder (ASD) is a set of neurodevelopmental disorders characterized by deficiencies in…
Read MoreCoincidence of primary adrenocortical carcinoma and melanoma: three CASE reports | Ko YL, et al | BMC Endocrine Disorders | Jan. 2023
Ko YL, Kumar V, Lippert J, Diaz-Cano S, Skordilis K, Kimpel O, Coincidence of primary adrenocortical carcinoma and melanoma: three CASE reports. BMC Endocrine Disorders. 2023 Jan;23(1):4. Nonacus products: Custom panels Background Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a heterogeneous prognosis, while adrenal metastasis from other primary cancers, including melanoma, may…
Read MoreNext generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46,XY DSD | Buonocore F, et al | Journal of the Endocrine Society | Dec. 2019
Buonocore F, Clifford-Mobley O, King TF, Striglioni N, Man E, Suntharalingham JP, et al. Next-generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46, XY DSD. Journal of the Endocrine Society. 2019;12:2341-60. Nonacus Products: Custom panels Context The genetic basis of human sex development is slowly being elucidated, and >40…
Read MoreEnhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR | Ghorashian S, et al | Nature medicine | Sep. 2019
Nonacus Products: Cell3 Target: Oncology Abstract Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL), but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19− clones. Some factors, including the choice…
Read More